ALZN
Alzamend Neuro Inc
NASDAQ: ALZN · HEALTHCARE · BIOTECHNOLOGY
$1.14
+7.55% today
Updated 2026-04-30
Market cap
$4.03M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.67
Dividend yield
—
52W range
$1 – $6
Volume
0.1M
Alzamend Neuro Inc (ALZN) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-18492.00 | $-1.42M | $-2.05M | $-1.05M | $-2.35M | $-2.71M | $-6.61M | $-8.92M | $-8.27M | $-6.57M |
| Capital expenditures | $0.00 | $0.00 | $0.00 | $106458.00 | $106458.00 | $106458.00 | $106458.00 | $0.00 | $147243.00 | $300000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $40980.00 | $114409.00 | $218417.00 | $396170.00 | $1.80M | $2.03M | $4.41M | $3.58M | $955633.00 | $325108.00 |
| Free cash flow | $-18492.00 | $-1.42M | $-2.05M | $-1.15M | $-2.45M | $-2.82M | $-6.72M | $-8.92M | $-8.42M | $-6.87M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | $1.84M | $12.13M | $-8.92M | — | — |